Announcement on Change of Accounting Policies
Filed with SSE · · 2 pages · Chinese
Summary by 6ix AI
Suzhou Zelgen Biopharmaceuticals Co. Ltd. announced a change in accounting policies.
Written in English by 6ix AI from the company’s Chinese-language filing. How 6ix writes summaries
Suzhou Zelgen Biopharmaceuticals Co. Ltd. on 6ix
Earlier from Suzhou Zelgen Biopharmaceuticals
- Science and Technology for People's Well-being - Achievement of Enterprises on SSE STAR Market and Its Empowerment of People's Livelihood Conference
- Announcement on Results of Shareholding Reduction by Shareholder, Director and Senior Management Member
- Announcement on Voluntary Disclosure of Results of the Phase III Clinical Trial of Gecacitinib Hydrochloride Tablets for the Treatment of Moderate to Severe Atopic Dermatitis Reaching the Primary Efficacy Endpoint
- Announcement on Voluntary Disclosure of Notice of Approval for Drug Clinical Trial Application Obtained by ZG006 Combined with HS-20093 for Injection, Either With or Without Adabepilimab Injection for the Treatment of Extensive-Stage Small Cell Lung Cancer
- Indicative Announcement on Change in Equity of Shareholders with Over 5% Shares Reaching 1% Scale
Later from Suzhou Zelgen Biopharmaceuticals
- Announcement on Voluntary Disclosure of Phase III Clinical Trial of Recombinant Human Thyrotropin β for Injection Reaching Prespecified Primary Endpoint
- Announcement on Voluntary Disclosure of Clinical Data and Latest Progress of ZG005 and ZG006 Released at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting
- Announcement on Using Partial Temporarily Idle Raised Funds for Cash Management
- Announcement on Voluntary Disclosure of the Approval of Marketing Application for Ivarmacitinib Hydrochloride Tablets for he Treatment of Severe Alopecia Areata
- Announcement on Resolutions of the 2025 Annual General Meeting
Follow Suzhou Zelgen Biopharmaceuticals into a list and get an email when it puts out news.
Follow Suzhou Zelgen Biopharmaceuticals